In a report released today, Ram Selvaraju from H.C. Wainwright reiterated a Buy rating on Bioxcel Therapeutics, with a price target of $10.00. The company’s shares closed yesterday at $2.68.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Selvaraju covers the Healthcare sector, focusing on stocks such as Bioxcel Therapeutics, Emergent Biosolutions, and Vanda. According to TipRanks, Selvaraju has an average return of 25.5% and a 57.66% success rate on recommended stocks.
Currently, the analyst consensus on Bioxcel Therapeutics is a Hold with an average price target of $8.25.
BTAI market cap is currently $52.65M and has a P/E ratio of -0.21.
Read More on BTAI:
Disclaimer & DisclosureReport an Issue
- BioXcel Announces Positive SERENITY At Home Study Results
- BioXcel announces results from correlation study from SERENITY At-Home trial
- Bioxcel Therapeutics: Buy Rating Affirmed Amid NASDAQ Compliance and Promising IGALMI™ Outlook
- BioXcel Therapeutics regains compliance with Nasdaq
- Bioxcel Therapeutics Files Current Report on Form 8-K
This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.
/Semiconductor%20by%20Gorodenkoff%20via%20Shutterstock.jpg)
/An%20image%20of%20a%20Tesla%20humanoid%20robot%20in%20front%20of%20the%20company%20logo%20Around%20the%20World%20Photos%20via%20Shutterstock.jpg)
